Work Here?
Berkeley Lights
Work Here?
Automated optofluidics platform for cell analysis
Berkeley Lights
Work Here?
Automated optofluidics platform for cell analysis
Overview
Berkeley Lights provides an integrated platform for accelerating cell-based research in biopharmaceuticals, cellular therapy, and genomics. The core product, the Berkeley Lights Platform, combines OptoSelect consumables, automation hardware, and application software to enable high-throughput single-cell analysis. It uses optofluidics, which uses light and fluidics to manipulate and profile thousands of cells in parallel, delivering detailed cell data. The company differentiates itself with an end-to-end solution that tightly integrates hardware, consumables, and software to speed up discovery and development of therapies, with a goal of helping customers achieve faster, more accurate results.
About Berkeley Lights
Industries
Robotics & Automation
Enterprise Software
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Debt Financing
Total Funding
$520.5M
Headquarters
Emeryville, California
Founded
2023
Simplify's Take
What believers are saying
- Beacon Select launch in January 2023 targets $2.8B cell line development market.
- Rabbit Memory B Cell workflow from November 2022 accesses novel antibody biodiversity.
- Consumables like OptoSelect chips generate 70%+ gross margin recurring revenue.
What critics are saying
- IsoPlexis integration causes 20-30% sales drop from platform overlap in 3-6 months.
- 10x Genomics' Chromium captures 70% single-cell market, sidelining optofluidics in 12-24 months.
- NVIDIA BioNeMo AI obsoletes Beacon chips as pharma adopts cloud simulation in 18-24 months.
What makes Berkeley Lights unique
- Optofluidics technology enables precise manipulation of thousands of single cells simultaneously.
- Integration with IsoPlexis' proteomics forms unique multi-omics functional cell biology platform.
- Beacon platform recovers live cells for antibody discovery and cell therapy development.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$520.5M
Above
Industry Average
Funded Over
8 Rounds
Benefits
Generous benefits package
Catered lunch every day!
Breakfast and snack foods
Workout classes with professional trainer
Sit/stand desks
Company social events
Referral bonus program
Paid parking
Free Shuttles from Bart and Walking Distance from Amtrak
Company News
/PRNewswire/ -- Berkeley Lights, Inc. (Nasdaq: BLI), a life sciences tools company, today announced that it has completed its previously announced acquisition...
Berkeley Lights, Inc. (Nasdaq: BLI), a life sciences tools company, today announced the launch of the Beacon Select ™, the company's new optofluidic system for cell line development (CLD).
Biology tools company Berkeley Lights will acquire IsoPlexis in a $57.8 million all-stock transaction agreement announced Wednesday.
Enables access to a broad range of biodiversity to find unique antibodies against challenging targets. EMERYVILLE, Calif., Nov. 18, 2022 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ: BLI), a leader in digital cell biology, today announced the launch of the Opto® Memory B Discovery Rabbit workflow, expanding the diversity of antibodies customers can discover on the Beacon® platform
Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced that Scott Chaplin has been named the Company's chief legal officer and corporate secretary, effective immediately.
There are no jobs for Berkeley Lights right now.
Find jobs on Simplify and start your career today
About Berkeley Lights
Industries
Robotics & Automation
Enterprise Software
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Debt Financing
Total Funding
$520.5M
Headquarters
Emeryville, California
Founded
2023
There are no jobs for Berkeley Lights right now.
Find jobs on Simplify and start your career today